Abstract:At present, the factors influencing Tuberculosis (TB) treatment effectiveness in HIV/TB co-infected patients need to be supported by more substantial real-world evidence. A retrospective study is conducted to fill the vacancy. 461 TB patients with HIV are defined as 742 samples according to each TB detection period. 7788 valid treatment records corresponding to 17 drug compositions for TB and 150 clinical indicators with more than 100 records are used to conduct data mining with consensus clustering, Fisher’s exact test, stratified analysis, and three modeling approaches, including logistic regression, support vector machine, and random forest. We find that A CD4+ T cell count of 42 cells per μL may serve as a sensitive classification standard for the immune level to assist in evaluating or predicting the efficacy of TB ( P =0.007); Rifabutin and levofloxacin alone or in combination may be more effective than other first- and second-line anti-TB agents in combination ( P =0.037); Samples with low immune levels (CD4≦42) may be more resistant to first-line TB drugs ( P =0.049); Age ( P =0.015), bicarbonate radical ( P =0.007), high-density lipoprotein cholesterol ( P =0.026), pre-treatment CD8+ T cell count ( P =0.015, age<60, male), neutrophil percentage ( P =0.033, age<60), rifabutin ( P =0.010, age<60), and cycloserine ( P =0.027, age<60) may influence the TB treatment effectiveness; More evidence is needed to support the relationship between pre-treatment clinical indicators or drug regimens and TB treatment effectiveness (The best AUC is 0.560∼0.763); The percentage of lymphocytes ( P =0.028) can be used as an effective TB therapeutic target. These perspectives supplement knowledge in relevant clinical aspects. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was funded by Funds for the key project of the Shanghai Public Health Clinical Center (KY-GW-2023-15); Shanghai Science and Technology Commission Medical Innovation Research Special Major Project (21Y31900400); Shanghai Science and Technology Commission Shanghai infectious diseases (AIDS) Clinical Medical Research Center Project (20MC1920100); Shenkang Hospital Development Center Clinical Science and Technology Innovation Project (SHDC22021317); Shanghai Municipal Science and Technology Critical Special Project "Research on Key Technologies for Prevention and Control of Major Sudden Infectious Diseases" (ZD2021CY001); Shenkang Hospital Development Center Clinical Research Basic Support Project (SHDC2020CR6025). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics Committee of Shanghai Public Clinical Center(No. 2020-S110-01) gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors

Effectiveness of C-Reactive Protein as a Tuberculosis Screening Test Among HIV-Infected Individuals - Shanghai, China, 2021-2023

The accuracy of point-of-care C-Reactive Protein as a screening test for tuberculosis in children

Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification Among Patients With Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-income Countries

Evaluation of C-Reactive Protein and Computer-Aided Analysis of Chest X-rays as Tuberculosis Triage Tests at Health Facilities in Lesotho and South Africa

A Clinical Prediction Score Including Trial of Antibiotics and C-Reactive Protein to Improve the Diagnosis of Tuberculosis in Ambulatory People With HIV

Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a prospective, cross-sectional, diagnostic accuracy study

Effect of Different Interventions for Latent Tuberculosis Infections in China: a Model-Based Study

Diagnostic Performance of Interferon-Gamma Releasing Assay in HIV-infected Patients in China.

Diagnostic accuracy of TB screening tests in a prospective multinational cohort: Chest-X-ray with computer-aided detection, Xpert TB host response, and C-reactive protein

Experience Of Offering Hiv Rapid Testing To At-Risk Patients In Community Health Centers In Eight Chinese Cities

A Retroactive Study on Factors Influencing the Efficacy of Treatment for Tuberculosis Patients with HIV: based on the data from 2010 to 2020 in Shanghai, China

Accuracy of C - Reactive protein as a bacterial infection marker in critically immunosuppressed patients: A systematic review and meta-analysis

Routinely Detected Indicators in Plasma Have a Predictive Effect on the Identification of HIV-infected Patients with Non-Tuberculous Mycobacterial and Tuberculous Infections.

The first 90: Progress in HIV detection in Zhejiang Province, 2008-2018

Positive rate and risk factors of latent tuberculosis infection among persons living with HIV in Jiangsu Province, China

Host blood protein biomarkers to screen for Tuberculosis disease: a systematic review and meta-analysis

Incidence of active tuberculosis in HIV-infected individuals not receiving universal tuberculosis preventive treatment

Performance of Xpert/MTB/RIF assay for childhood pulmonary tuberculosis among HIV negative children with real world evidence in China

Discovery of Potential Plasma Biomarkers for Tuberculosis in HIV-Infected Patients by Data-Independent Acquisition-Based Quantitative Proteomics.

Screening of tuberculosis infection in household contacts by interferon γ release assay and tuberculin skin test to predict active tuberculosis in China

Clinical diagnostic value of CRISPR-Cas13a-based molecular technology for tuberculosis